Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350968 | 1.00 | IDO1 (0.53) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL29400614 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL30261869 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL30648981 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL872021 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL3722284 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL46349 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL29362906 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL29357117 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 | |
| SCHEMBL29460393 | 0.91 | MDM4 (0.55) | IDO1MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| CN-119119190-A | Melanocortin receptor ligands | 益普生制药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-105837661-B | Melanocortin receptor ligands | 益普生制药股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | IDO1 269/4885MDM2 3806/4885MDM4 4714/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | IDO1 1309/4885MDM2 3975/4885MDM4 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.